The clinical efficacy of capecitabine combined with docetaxel in treatment of patients with locally advanced breast cancer and its influence on immune function
10.3760/cma.j.issn.1008-6706.2017.10.027
- VernacularTitle:卡培他滨联合多西紫杉醇对局部晚期乳腺癌患者的临床疗效及免疫功能的影响
- Author:
Xiaomin JIN
;
Yan SUN
;
Jing LI
- Keywords:
Breast neoplasms;
Immunoglobulins;
Docetaxel;
Capecitabine
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(10):1543-1546
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of docetaxel combined with capecitabine in the treatment of patients with locally advanced breast cancer and its effect on immune function.Methods 160 patients with locally advanced breast cancer were randomly divided into observation group and control group.The control group was treated with capecitabine.The patients in the observation group were treated with docetaxel combined with capecitabine.The clinical effective rate, median time to progress, median survival time, one year survival rate and immunoglobulin protein expression levels were observed.Results The clinical effective rate and stable rate in the observation group were 88.75% and 95.00%, which were significantly higher than 68.75% and 87.50% in the control group, the differences were statistically significant (x2=5.89,4.17,all P<0.05).After treatment, the median time to progression, median survival time and one year survival rate of the observation group were significantly higher than those of the control group (t=3.43,5.09,6.23,all P<0.05).Compared with before treatment, after treatment, the IgG,IgM and IgA levels in the observation group significantly decreased(t=2.34,3.16,3.27,all P<0.05), while those of the control group were not significantly changed (t=0.79,0.22,0.27,all P>0.05).Conclusion Docetaxel combined with capecitabine in the treatment of patients with locally advanced breast cancer can improve the clinical efficacy and stability, prolong the survival time of patients.Compared with using single agent chemotherapy, combined use has no significant effect on human immune function, the effect is better than the use of capecitabine alone, which is worthy of promotion in clinical use.
